NYSE:NUVBPharmaceuticals
Why Nuvation Bio (NUVB) Is Down 8.2% After Expanding Global Taletrectinib Partnership With Eisai
Nuvation Bio Inc. and Eisai Co. Ltd. recently signed an exclusive license and collaboration agreement that grants Eisai rights to develop, register and commercialize taletrectinib (IBTROZI) for ROS1-positive non-small cell lung cancer across Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand and multiple Asian markets, in exchange for an upfront payment of €50 million (about US$60 million), potential milestones up to €145 million (about US$170 million) and...